MedPath

Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression

Not Applicable
Completed
Conditions
Major Depression
Registration Number
NCT00149071
Lead Sponsor
Hillerod Hospital, Denmark
Brief Summary

A doubleblind randomised trial with active versus sham rTMS in combination with escitalopram in patients with prior treatment resistant depression in an acute 12 weeks trial with subsequent 24 weeks study phase with active versus placebo citalopram

Detailed Description

In this study we aimed at investigating to what degree rTMS applied over the left dorsolateral cortex relieves depressive symptoms when the treament is combined with antidepressive medication. The study will also be able to supply knowledge on how long any possible effect of the rTMS treatment lasts.

In the first 12 weeks of the trial participants are randomised to either rTMS combined with escitalopram or sham rTMS combined with escitalopram. rTMS is given daily for the first 3 weeks.

The next phase is a relapse prevention study where the responders from the initial phase are randomised to either active or placebo escitalopram for 24 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
61
Inclusion Criteria
  • Major depression Hamilton score above 18
  • Age 18 to 75
Exclusion Criteria
  • Pregnancy og breastfeeding
  • Mental retardation and organic brain disease
  • Alcohol and substance abuse
  • Metal implants in brain, pacemakers and other electronic implants

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
depression scores6 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Psychiatric research unit, Hilleroed Hospital,

🇩🇰

Hillerod, Denmark

Psychiatric research unit, Hilleroed Hospital,
🇩🇰Hillerod, Denmark
© Copyright 2025. All Rights Reserved by MedPath